We used the Kras mutant, mouse colon carcinoma cell line CT26, based on its immunogenicity and sensitivity to anti-PD-L1 antibody therapy, making it suitable for downstream in vivo experiments. The gene discussed is KRAS; the disease is colon carcinoma.